AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says

기사 요약

FDA approves AbbVie's Juvmo for Parkinson's disease, the first D1/D5 agonist. U.S. launch set for Oct 2026. Get pricing and sales data.